Search


Swiss Nordic Bio 2026: Amphilix believes in using small ligands and small molecule linkers for radiopharmaceuticals - the lead program will target GPL4
Founder and Chairman Kevin McAllister describes the platform and why he believes theirs is a better approach to radiopharmaceuticals. Coverage brought to you by
1 hour ago






.png)